Tags

Type your tag names separated by a space and hit enter

A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution.
Eur J Ophthalmol. 2006 May-Jun; 16(3):407-15.EJ

Abstract

PURPOSE

To compare the intraocular pressure lowering efficacy and side effect profile of travoprost 0.004%/timolol 0.5% ophthalmic solution dosed in the morning and evening.

METHODS

This was a multicenter, prospective, randomized, double-masked, parallel group clinical study of 92 patients with open-angle glaucoma (with or without pseudoexfoliative or pigmentary glaucoma) or ocular hypertension. After a washout of existing glaucoma medications, patients were randomly assigned to receive one drop of travoprost 0.004%/timolol 0.5% in the morning or evening for 6 weeks. The main outcome measures were mean intraocular pressure (IOP) assessed at 9 am, 11 am, and 4 pm, and safety variables.

RESULTS

Travoprost 0.004%/timolol 0.5% ophthalmic solution, dosed in the morning or evening, controlled IOP consistently throughout the day. Mean IOP ranged from 16.5 to 16.7 mmHg in the morning treatment group and from 16.1 to 17.2 mmHg in the evening treatment group. Travoprost 0.004%/timolol 0.5% ophthalmic solution produced statistically significant and clinically relevant reductions in IOP from baseline; mean reductions ranged from approximately 8 to 10 mmHg (32% to 38%). Travoprost 0.004%/timolol 0.5% ophthalmic solution was safe and well tolerated with the most frequently reported adverse event being ocular hyperemia, which occurred in 12.5% of patients in the morning treatment group and 13.6% of patients in the evening treatment group.

CONCLUSIONS

Travoprost 0.004%/timolol 0.5% given once daily, either in the morning or evening, is a safe and effective treatment for open-angle glaucoma and ocular hypertension. It may be beneficial for patients judged to be inadequately controlled on a prostaglandin analogue or ophthalmic beta-blocker alone.

Authors+Show Affiliations

Hôpital Edouard Herriot, Lyon--France. phillippe.denis@chu-lyon.frNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16761242

Citation

Denis, P, et al. "A Comparison of Morning and Evening Instillation of a Combination Travoprost 0.004%/timolol 0.5% Ophthalmic Solution." European Journal of Ophthalmology, vol. 16, no. 3, 2006, pp. 407-15.
Denis P, Andrew R, Wells D, et al. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol. 2006;16(3):407-15.
Denis, P., Andrew, R., Wells, D., & Friren, B. (2006). A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. European Journal of Ophthalmology, 16(3), 407-15.
Denis P, et al. A Comparison of Morning and Evening Instillation of a Combination Travoprost 0.004%/timolol 0.5% Ophthalmic Solution. Eur J Ophthalmol. 2006 May-Jun;16(3):407-15. PubMed PMID: 16761242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. AU - Denis,P, AU - Andrew,R, AU - Wells,D, AU - Friren,B, PY - 2006/6/9/pubmed PY - 2006/8/8/medline PY - 2006/6/9/entrez SP - 407 EP - 15 JF - European journal of ophthalmology JO - Eur J Ophthalmol VL - 16 IS - 3 N2 - PURPOSE: To compare the intraocular pressure lowering efficacy and side effect profile of travoprost 0.004%/timolol 0.5% ophthalmic solution dosed in the morning and evening. METHODS: This was a multicenter, prospective, randomized, double-masked, parallel group clinical study of 92 patients with open-angle glaucoma (with or without pseudoexfoliative or pigmentary glaucoma) or ocular hypertension. After a washout of existing glaucoma medications, patients were randomly assigned to receive one drop of travoprost 0.004%/timolol 0.5% in the morning or evening for 6 weeks. The main outcome measures were mean intraocular pressure (IOP) assessed at 9 am, 11 am, and 4 pm, and safety variables. RESULTS: Travoprost 0.004%/timolol 0.5% ophthalmic solution, dosed in the morning or evening, controlled IOP consistently throughout the day. Mean IOP ranged from 16.5 to 16.7 mmHg in the morning treatment group and from 16.1 to 17.2 mmHg in the evening treatment group. Travoprost 0.004%/timolol 0.5% ophthalmic solution produced statistically significant and clinically relevant reductions in IOP from baseline; mean reductions ranged from approximately 8 to 10 mmHg (32% to 38%). Travoprost 0.004%/timolol 0.5% ophthalmic solution was safe and well tolerated with the most frequently reported adverse event being ocular hyperemia, which occurred in 12.5% of patients in the morning treatment group and 13.6% of patients in the evening treatment group. CONCLUSIONS: Travoprost 0.004%/timolol 0.5% given once daily, either in the morning or evening, is a safe and effective treatment for open-angle glaucoma and ocular hypertension. It may be beneficial for patients judged to be inadequately controlled on a prostaglandin analogue or ophthalmic beta-blocker alone. SN - 1120-6721 UR - https://www.unboundmedicine.com/medline/citation/16761242/A_comparison_of_morning_and_evening_instillation_of_a_combination_travoprost_0_004/timolol_0_5_ophthalmic_solution_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=16761242.ui DB - PRIME DP - Unbound Medicine ER -